Zhang and Mao, respectively, showed that apoA-I, in conjunction with apoA-I binding protein (AIBP), can enhance cholesterol reverse transport, inhibit inflammation and angiogenesis, and decrease the development of neo-atherosclerosis [29–33]. Here, APOA1 is linked to atherosclerosis.